Who owns OCUPHIRE PHARMA INC?
- Ticker: IRD
- CUSIP Number: 67577r102
Tip: Access positions for across all investors
Analyze quarterly positions in Ocuphire Pharma with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Ocuphire Pharma stock
Who bought or sold OCUPHIRE PHARMA INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| BIOS Capital Management | 3.7M | $17M | 0% | Mar 2026 |
|
| Balyasny Asset Management | 2.7M | $12M | 0% | Mar 2026 |
|
| Millennium Management | 2.6M | $12M | 31% | Mar 2026 |
|
| Vanguard Capital Management | 2.4M | $11M | 100% | Mar 2026 |
|
| Vanguard Group | 2.3M | $4.7M | 73% | Dec 2025 |
|
| ADAR1 Capital Management | 1.8M | $8.4M | 4523% | Mar 2026 |
|
| Perceptive Advisors | 1.8M | $8.4M | -58% | Mar 2026 |
|
| Nantahala Capital Management | 1.7M | $7.7M | -65% | Mar 2026 |
|
| Woodline Partners | 1.4M | $6.2M | 100% | Mar 2026 |
|
| Boothbay Fund Management | 1.2M | $5.4M | 100% | Mar 2026 |
|
| Opaleye Management | 1.1M | $2.3M | 0% | Mar 2026 |
|
| Adage Capital Partners GP | 1.1M | $2.2M | 16% | Dec 2025 |
|
| Bleichroeder | 737k | $1.5M | 0% | Dec 2025 |
|
| Mink Brook Asset Management | 591k | $2.7M | -65% | Mar 2026 |
|
| Geode Capital Management | 538k | $2.5M | 7% | Mar 2026 |
|
| Trails Edge Capital Partners | 500k | $2.3M | 100% | Mar 2026 |
|
| Voss Capital | 442k | $888k | -21% | Dec 2025 |
|
| Ameriprise Financial | 389k | $1.8M | 100% | Mar 2026 |
|
| Goldman Sachs Group | 327k | $1.5M | 100% | Mar 2026 |
|
| Dr. Jeffrey R. Jay, M.D. | 324k | $1.5M | 100% | Mar 2026 |
|
| Vanguard Fiduciary Trust | 282k | $1.3M | 100% | Mar 2026 |
|
| UBS Group | 258k | $1.2M | 187% | Mar 2026 |
|
| Susquehanna International | 248k | $498k | 1126% | Dec 2025 |
|
| Jane Street | 202k | $917k | 100% | Mar 2026 |
|
| State Street Corporation | 173k | $348k | 19% | Dec 2025 |
|
| Marshall Wace | 158k | $317k | 100% | Dec 2025 |
|
| BlackRock | 148k | $672k | 4% | Mar 2026 |
|
| Voleon Capital Management | 144k | $654k | 100% | Mar 2026 |
|
| Seven Fleet Capital Management | 134k | $611k | 100% | Mar 2026 |
|
| Creative Planning | 128k | $584k | 0% | Mar 2026 |
|
| Renaissance Technologies | 126k | $254k | -27% | Dec 2025 |
|
| Citadel Advisors | 121k | $550k | -33% | Mar 2026 |
|
| Two Sigma Investments | 109k | $494k | -28% | Mar 2026 |
|
| Texas Capital Bank Wealth Management Services | 89k | $403k | 13% | Mar 2026 |
|
| Northern Trust | 87k | $176k | 28% | Dec 2025 |
|
| Regency Capital Management | 68k | $309k | 48% | Mar 2026 |
|
| Hrt Financial | 68k | $307k | 100% | Mar 2026 |
|
| Bank of America Corporation | 67k | $305k | 100% | Mar 2026 |
|
| Brevan Howard Capital Management | 61k | $279k | 100% | Mar 2026 |
|
| Empowered Funds | 42k | $85k | 0% | Dec 2025 |
|
| Bridgeway Capital Management | 42k | $85k | 0% | Dec 2025 |
|
| OMERS Administration Corporation | 42k | $189k | -53% | Mar 2026 |
|
| Qube Research & Technologies | 40k | $80k | 100% | Dec 2025 |
|
| Morgan Stanley | 40k | $180k | 38% | Mar 2026 |
|
| Captrust Financial Advisors | 32k | $64k | 0% | Dec 2025 |
|
| nVerses Capital | 29k | $130k | 100% | Mar 2026 |
|
| XTX Topco | 24k | $48k | -54% | Dec 2025 |
|
| Vanguard Global Advisers | 22k | $101k | 100% | Mar 2026 |
|
| Miller Financial Services | 22k | $100k | 120% | Mar 2026 |
|
| Raymond James Financial | 21k | $41k | -9% | Dec 2025 |
|
| Persistent Asset Partners | 18k | $82k | 100% | Mar 2026 |
|
| Virtu Financial | 17k | $34k | 100% | Dec 2025 |
|
| James Investment Research | 16k | $75k | 0% | Mar 2026 |
|
| Goss Wealth Management | 16k | $75k | 0% | Mar 2026 |
|
| Bedel Financial Consulting | 15k | $68k | 0% | Mar 2026 |
|
| Advisor Group Holdings | 14k | $28k | 0% | Dec 2025 |
|
| Kestra Private Wealth Services | 13k | $58k | -20% | Mar 2026 |
|
| William Blair $ Company | 13k | $57k | -55% | Mar 2026 |
|
| Stokes Family Office | 12k | $55k | 0% | Mar 2026 |
|
| Sanders Morris Harris | 12k | $55k | 100% | Mar 2026 |
|
| Brian McDonald | 12k | $24k | 0% | Dec 2025 |
|
| First City Capital Management | 12k | $54k | 0% | Mar 2026 |
|
| Group One Trading | 11k | $48k | 100% | Mar 2026 |
|
| Reliant Investment Partners | 10k | $46k | 0% | Mar 2026 |
|
| Annandale Capital | 10k | $46k | 0% | Mar 2026 |
|
| Simplex Trading | 9.1k | $18k | -72% | Dec 2025 |
|
| Hilton Head Capital Partners | 4.5k | $20k | 100% | Mar 2026 |
|
| Wells Fargo & Company | 3.8k | $17k | -98% | Mar 2026 |
|
| Farther Finance Advisors | 2.3k | $11k | 100% | Mar 2026 |
|
| National Bank Of Canada /fi/ | 2.0k | $4.0k | 0% | Dec 2025 |
|
| Barclays | 1.9k | $3.8k | 0% | Dec 2025 |
|
| SBI Securities | 530.00 | $2.4k | -79% | Mar 2026 |
|
| International Assets Investment Management | 521.00 | $2.4k | 0% | Mar 2026 |
|
| Royal Bank of Canada | 5.00 | $0 | -83% | Mar 2026 |
|
| Hanson McClain Advisors | 5.00 | $11.000000 | 100% | Dec 2025 |
|
Who sold out of Ocuphire Pharma?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Johnson Investment Counsel | Dec 2025 | 20k | $40k |
| Occudo Quantitative Strategies | Dec 2025 | 12k | $25k |